December 18, 2014 6:02 AM ET

Biotechnology

Company Overview of Avigen, Inc.

Company Overview

Avigen, Inc. offers biopharmaceutical services and engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials...

1301 Harbor Bay Parkway

Alameda, CA 94502

United States

Founded in 1992

12 Employees

Phone:

510-748-7150

Fax:

510-748-7155

Key Executives for Avigen, Inc.

Chief Executive Officer and President
Age: 47
Co-Founder
Age: 60
Head of Regulatory Affairs
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Neurotech Pharmaceuticals, Inc. United States
Nucleonics, Inc. United States
MonoSol Rx Inc. United States
Genetics Institute, LLC United States
BioProtect Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Avigen, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.